Food Allergy Diagnostics Therapeutics Market Size, Share - Growth Analysis Report and Forecast Trends 2026-2030

The Food Allergy Diagnostics & Therapeutics market comprises products and services used to identify, monitor, and manage immune-mediated adverse reactions to specific foods including peanuts, tree nuts, milk, eggs, shellfish, fish, soy, and wheat. The diagnostics segment includes in vitro testing systems, skin prick test devices, atopic patch tests, and advanced component-resolved diagnostics that identify specific allergenic proteins. Therapeutic offerings range from established allergen immunotherapy approaches to emerging biologic treatments targeting specific immune pathways.

• •Market valued at approximately $7.04 billion globally in 2025
• •Diagnostics segment represents the larger portion of total market revenue
• •Key end-users include hospitals, clinical laboratories, specialty clinics, and research institutions

Rising prevalence of food allergies remains a fundamental market support factor, with food allergies affecting an estimated 8 percent of children and up to 5 percent of adults in many developed countries. Increasing disease awareness among both healthcare providers and patients has driven higher diagnostic testing rates, while increasingly stringent food labeling regulations in regions including the European Union, United States, and other major markets have created sustained demand for allergen testing services. Additionally, ongoing research into food allergy mechanisms continues to advance diagnostic precision and therapeutic development.

• •Growing incidence of food allergies globally, particularly in pediatric and urban populations
• •Mandatory allergen labeling regulations in major markets sustaining diagnostic demand
• •Improved disease awareness leading to earlier detection and higher testing rates

The market is broadly segmented into diagnostic products and therapeutic products, with diagnostics comprising the majority share due to the essential role of testing in allergy confirmation and management. By allergen type, peanut, milk, and egg allergies represent the largest segments given their high prevalence in children, while emerging segments focus on sesame, mustard, and other allergens gaining regulatory attention. Geographically, North America commands the largest regional share due to high allergy prevalence and advanced healthcare infrastructure, followed by Europe, while Asia-Pacific represents an emerging growth area driven by rising allergy rates in developing economies.

• •North America leads regional markets due to high disease prevalence and healthcare investment
• •Europe holds a strong position supported by comprehensive regulatory frameworks and allergy awareness
• •Asia-Pacific and Latin America emerging as growth markets with rising diagnostic adoption

What are the recent trends and outlook?

The market's current flat growth trajectory reflects a transitional phase where traditional diagnostic technologies have achieved saturation in mature markets while novel therapeutic modalities navigate extended regulatory approval timelines. Component-resolved diagnostics and multiplex testing platforms represent current innovation trends, offering improved specificity and reduced testing time. Over the longer term, market renewal may come from precision medicine approaches, digital health integration, and the eventual commercialization of biologic therapies currently in clinical development.

• •Component-resolved diagnostics gaining clinical adoption for precise allergen identification
• •Biologic treatments and improved immunotherapy protocols advancing through clinical trials
• •Digital health platforms and AI-assisted diagnostic tools emerging as future innovation areas